#TumorBoardTuesday I hope everyone in the🇺🇸&🇨🇦has survived the🥶 Let's warm up🔥to some learning😉 📢Join us TONIGHT, 01-21-25 at 8PM ET as Sharlene Gill, MD, MPH, MBA, FASCO & Cynthia🗣️TAS-102⛔️in refractory metastatic #colorectalcancer RT and bring others into the discussion‼️

#TumorBoardTuesday 🧠And while we finalize the case details, collect FREE #CME 👉🏽integrityce.com/TBT2024 #OncTwitter

#TumorBoardTuesday ➡️Before Sharlene Gill, MD, MPH, MBA, FASCO & Cynthia🗣️the use of TAS-102⛔️in refractory metastatic #colorectalcancer, tell us your connection to this medical🩺discussion 👇👇🏼👇🏾

Cynthia #TumorBoardTuesday Both tucatinib+trastuzumab and TDxd are meaningful options in HER2+ mCRC…if only they were available in 🇨🇦 🙏

A.n.n. Cynthia #TumorBoardTuesday David S. Hong MD george demetri HongYi925 Great Q - I would favor IO, ideally nivo-ip per CM 8HW with NTRK⛔️after IO progression.

Cynthia #TumorBoardTuesday David S. Hong MD george demetri Journal of Clinical Oncology #TumorBoardTuesday Just to put it out there as a reminder - TAS-102 is not the same as 5-FU 😉 😕But - who came up with that Day 1-5, Day 8-12 Q28 schedule Writing that script is EPIC is so challenging🤣

Cynthia #TumorBoardTuesday David S. Hong MD george demetri Journal of Clinical Oncology #TumorBoardTuesday 👏Kudos to the SOREGATT and SUNLIGHT authors for a methodical, stepwise approach to challenging the standard of care (Rather than a Phase I➡️Phase 3 leap of faith)

Cynthia #TumorBoardTuesday David S. Hong MD george demetri Journal of Clinical Oncology Colorectal Cancer Canada @elena_elez Arvind Dasari, MD, MS #TumorBoardTuesday 🧑‍🏫Excellent point - regorafenib was not tested in TAS-102 refractory patients The one downside to being first❓

Cynthia #TumorBoardTuesday David S. Hong MD george demetri Journal of Clinical Oncology Colorectal Cancer Canada @elena_elez Arvind Dasari, MD, MS CCTG #TumorBoardTuesday We need to make clinical trial enrollement more feasible ✅Help patients find trials ✅Facilitate enrollement ✅Complete accrual with a truly representative patient population

What a great discussion on refractory #colorectalcancer! Thank you for hosting us #TumorBoardTuesday and Mike Pishvaian!

Outcomes of patients with peritoneal-limited metastatic gastric cancer undergoing bidirectional CTx cytoreductive surgery with HIPEC #ASCOGI25 🔎 PRECISE-SG 1, single center RWD 👉mPFS 9.5 👉mOS 17.5mo 👉Surgery associated w/ better OS ESMO - Eur. Oncology

Trastuzumab with or without pertuzumab for peri-op CTx of HER-2+ GC #ASCOGI25 🔎EORTC-1203 GITC INNOVATION 👉mpRR: 23 vs 37 vs 26% 👉3yr OS rate: 75 vs 76 vs 65% 👉High Tox for CTx + T + P 🧐 Negative trial, but high mpRR by adding T to CTx ESMO - Eur. Oncology

#GI25 Is it the hardest to pronounce name of any antibody? Yes. It is also probably the best new treatment for GI malignancies? Also, probably yes. Daraxonrasib, pan-KRASi Amazing responses in second line PDAC Making the undruggable druggable. (Someone please teach me how to

Single-cycle of neoadj. pembrolizumab in stage I-III dMMR/MSI CRC #ASCOGI25 🔎Final analysis of RESET-C phs-2, 85 pts 👉pCR: 44%, mPR: 57% 👉higher pCR rate in stage I-II 👉No new safety signals 🧐amazing: a single cycle sufficed to achieve pCR in some pts > on the way to WW in

#GI25 ASCO 🌟 Practice-changing ALASCCA ph3 trial 🇸🇪 📌 ASA 160mg in PIK3CA+ stage II-III #CRCsm 📌 PIK3CA+ in 37% ➡️ HR 0.42 for 3yr DFS! OncoAlert

#GI25 ❤️ ASCO So proud to see our past and present #oncology trainees thriving & making their mark! Jp Solar Vasconcelos Jonathan Loree Cynthia Howie 🇨🇦 BC Cancer @UBCmedicine

Congratulations to this year’s class of Conquer Cancer grant and award recipients! Are you one of them? Tell us in the comments! We can't wait to celebrate with you at #ASCO25. Full list of recipients: brnw.ch/21wSR0A ASCO

#ASCO25 ASCO CM577 adj nivo in resected yp+ esoph/GEJ after CRT 📌 SOC based on DFS ➡️ trend for OS - improved by 15mos - benefit in SCC, PDL1+ ➡️worse OS in PDL1- ⛔️ ✅Reaffirms benefit of adj nivo in PDL1+ ‼️PDL1 testing needed 🤔how will this cf ESOPEC & MATTERHORN

🔥Plenary Discussion of LBA1🔥 #ASCO2025 👏Excellent disucssion by Myriam Chalabi 👉May neoadjuvant be more effective? 👉Do we need chemotherapy? ESMO - Eur. Oncology

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.